AbCellera Biologics (NASDAQ:ABCL – Free Report) had its price objective reduced by Benchmark from $20.00 to $12.00 in a report released on Thursday morning, MarketBeat.com reports. They currently have a buy rating on the stock. Several other research analysts also recently weighed in on ABCL. SVB Securities reduced their target price on AbCellera Biologics from […]
Capula Management Ltd Invests $449,000 in AbCellera Biologics Inc (NASDAQ:ABCL) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) – Research analysts at Bloom Burton boosted their Q3 2023 EPS estimates for AbCellera Biologics in a research report issued on Monday, August 7th. Bloom Burton analyst A. Borovina now expects that the company will earn ($0.12) per share for the quarter, up from their previous estimate of […]
Prime Capital Investment Advisors LLC bought a new stake in AbCellera Biologics Inc. (NASDAQ:ABCL – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,432 shares of the company’s stock, valued at approximately $147,000. Several other hedge funds have also recently […]
Shares of AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) have received a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on […]